Document:

Amendment to License and Sublicense Agreement, dated February 22, 2006

 Exhibit 10.2 
 Execution Copy 
 AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT 
 BY AND BETWEEN 
 CPEC LLC AND ARCA
DISCOVERY INC. 
 THIS AMENDMENT (the “Amendment”), dated as of February, 22, 2006 (“Amendment Effective Date”), by
and between CPEC LLC, a Delaware limited liability company having an office at 33 Hayden Avenue, Lexington, MA 02421 (“CPEC”) and ARCA Discovery, Inc., a corporation organized and existing under the laws of the State of Colorado and having
its principal office at 1400 Sixteenth Street, Suite 220, Denver, Colorado 80202 (“ARCA”), amends the License and Sublicense Agreement effective as of October 28, 2003 (the “License Agreement”) by and between CPEC and ARCA.

 WITNESSETH: 
 WHEREAS, CPEC and ARCA desire to amend the License Agreement upon the terms and conditions set forth herein, effective as of the Amendment Effective Date. 
 NOW, THEREFORE, in consideration of the premises contained herein, and for other good and valuable consideration, the adequacy and receipt of which are hereby acknowledged, the parties hereto agree,
effective as of the Amendment Effective Date, as follows: 
 1. Except as otherwise defined herein, all defined terms used herein shall have the meanings set
forth in the License Agreement. 
 2. Article 1 of the License Agreement is hereby amended to add the following new Sections to the end thereof: 

“1.30 “ARCA’s Series A Preferred Stock Financing” shall mean ARCA’s first preferred stock financing on
or subsequent to the Amendment Effective Date which, in one or more closings, raises an aggregate of at least $5 million in new funds. 
 1.31 “Equity Agreements” shall mean the Subscription Agreement in the form attached as Exhibit A, the Voting Agreement in the form attached as Exhibit B, the Investor Rights Agreement in the form
attached as Exhibit C and the Right of First Refusal and Co-Sale Agreement in the form attached as Exhibit D.” 
 3. Section 3.2.2 of the License
Agreement is hereby amended and restated to read in its entirety as follows: 
 “3.2.2 In addition to the diligence
obligations set forth in Section 3.2.1 above, ARCA shall also: 
 (a) complete ARCA’s Series A Preferred Stock Financing within
three (3) months of the Amendment Effective Date; and 

 (b) either (i) receive an Institutional Review Board (“IRB”) approval of the protocol for
a Phase 3 clinical trial with Product (after an End of Phase 2 Meeting) in patients with congestive heart failure within twelve (12) months after the Amendment Effective Date and commence such Phase 3 clinical trial within three (3) months
after such IRB approval, and have raised sufficient financing to complete such trial prior to its commencement; or (ii) within eighteen (18) months of the Amendment Effective Date either (A) file an NDA for Product or (B) obtain
an agreement with the FDA to permit a rolling review of the NDA for Product and file the initial section of such NDA in accordance with such agreement.” 
 4. Section 5.1 of the License Agreement is hereby amended and restated to read in its entirety as follows: 
 “5.1 Milestone Payments. Subject to the terms and conditions contained in this Agreement, and in consideration of the rights granted by CPEC hereunder, ARCA shall pay CPEC the following milestone payments, contingent upon
occurrence of the specified event: 
 (a) US $1,000,000 upon the closing of ARCA’s Series A Preferred Stock Financing; 
 (b) US $500,000 upon the submission of an NDA with the FDA; 
 (c) US $250,000 upon [ * ]; 
 (d) US $250,000 upon [ * ]; 
 (e) US $8,000,000 within six (6) months of obtaining Regulatory Approval for marketing in the United States by the FDA; 
 (f) US $2,750,000 within six (6) months of [ * ]; and 
 (g) US $1,750,000 within six (6) months of [ * ]. 
 For clarification, the parties
acknowledge and agree that the first date of any rolling, initial or partial submission of any NDA or any portion or section of an NDA shall constitute the date of submission of an NDA for purposes of the foregoing milestone payments. ARCA shall
notify CPEC in writing within ten (10) days after the achievement of each milestone and such notice shall be accompanied by the appropriate milestone payment.” 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 2 

 5. Section 5.2.1 (i) of the License Agreement is hereby amended and restated to read in its entirety as
follows: 
 “(i) Subject to the terms and conditions of this Agreement, and in further consideration of the rights
granted by CPEC hereunder, ARCA shall pay to CPEC royalties in the applicable percentage set forth below for Net Sales in each Royalty Year of Products by ARCA, its Affiliates or sublicensees: 
  

				
	 Annual Net Sales:
	  	Royalty Rate:	 
	Up to the first [ * ]:	  	7.5	%
	Over [ * ] and up to [ * ]:	  	10	%
	Over [ * ]:	  	20	%”

 6. Section 5.2 of the License Agreement is hereby amended to add at the end thereof a new Section 5.2.4
which shall read in its entirety as follows: 
 “5.2.4 Royalty Buy-Down. At
any time during the period commencing on the Effective Date and expiring [ * ] after obtaining Regulatory Approval for marketing Product in the United States (the “Option Period”), ARCA shall have the option to buy-down the
royalty rates set forth in Section 5.2.1 (i) as follows: For annual Net Sales over [ * ], and up to [ * ], ARCA shall have the option to buy-down up to two and one-half (2 1/2) percentage points (down to a rate of 7.5%), and for annual Net Sales over [ * ], ARCA shall have the option to buy-down up to eight (8) percentage points
(down to a rate of 12%). To exercise the buy-down option, ARCA shall provide CPEC with a written notice electing to exercise the buy-down option at any time during the Option Period and, within [ * ] thereafter, pay to CPEC [ * ]
reduction in royalty rate. The applicable royalty rate reduction shall be effective as of the date the related payment is made in full to CPEC.” 
 7. Article V of the License Agreement is hereby amended to add at the end thereof a new Section 5.8 which shall read in its entirety as follows: 
 “5.8. Equity Issuance. Subject to the terms and conditions contained in this Agreement and the Equity Agreements and in
further consideration of the rights granted by CPEC hereunder and pursuant to the Amendment, ARCA shall, on the Amendment Effective Date, issue to CPEC and/or its designees an aggregate of 400,000 shares of ARCA’s Common Stock, $.001 par value
per share. 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 3 

 8. Section 9.4 of the License Agreement is hereby amended by: 
 (a) replacing the address of ARCA with the following: 
 “ARCA Discovery, Inc. 
 1400 16th Street 
 Suite 220 
 Denver, CO 80202 
 Attention: President and
Chief Executive Officer 
 Fax No.: 303-825-0883”; 
 and 
 (b) replacing the address of CPEC with the following: 
 CPEC LLC 
 33 Hayden Avenue 
 Lexington, MA 02421 
 Attention: Chief
Executive Officer 
 Fax No.: 781-862-3859” 
 9. Except as expressly amended or waived by this Amendment, all of the provisions of the License Agreement shall remain in full force and effect. All references to the License Agreement, from and after the Amendment Effective Date, shall be
to the License Agreement as amended by this Amendment. 
 10. In the event that any of the provisions contained in this Amendment are held invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties. In such event, the Parties shall replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purpose of this Amendment.

 11. This Amendment shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflicts of
law. 
 12. The waiver by a Party hereto of any right hereunder or the failure to perform or of a breach by another Party shall not be deemed a waiver of any
other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 
 13. This Amendment may be executed
in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 4 

 IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first set forth above.

  

			
	CPEC LLC.
		
	By:	 	/s/ Mark S. Butler
	Name:	 	Mark S. Butler
	Title:	 	Executive Vice President
	
	ARCA DISCOVERY, INC.
		
	By:	 	/s/ Michael R. Bristow
	Name:	 	Michael R. Bristow
	Title:	 	President and Chief Executive Officer

  

 5 

 Exhibit A 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 6 

 Exhibit B 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 7 

 Exhibit C 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 8 

 Exhibit D 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 9Exclusive License Agreement, dated October 14, 2005

 Exhibit 10.3 
 EXCLUSIVE LICENSE AGREEMENT 
 For Licensing Patent Rights 
 This Agreement is made and entered into by and between THE REGENTS OF THE UNIVERSITY OF COLORADO,
a body corporate, having its principal office at 201 Regent Hall, Regent Drive, Boulder, CO 80309 (hereinafter “University”) and ARCA Discovery, Inc., a Delaware corporation having its principal office at 1400 16th Street, Suite 220, Denver, CO 80202 (hereinafter “Licensee”). 
 WITNESSETH 
 WHEREAS, University is the owner of certain Patent Rights (as later defined
herein) relating to expression profiling in the intact human heart and a method of treating heart failure with bucindolol, identified as University Case nos. 2002.026H, CU1297H and CU1298H, developed by inventors Michael Bristow et. al, and
has the right to grant licenses under said Patent Rights; and 
 WHEREAS, University has granted certain rights to such Patents Rights to
Myogen, Inc. (“Myogen”); and 
 WHEREAS, Myogen has relinquished some of its rights in the Patent Rights and has permitted
University the right to grant certain licenses under said Patent Rights; and 
 WHEREAS, Licensee is interested in licensing and further
developing the Patent Rights for commercial applications; and 
 WHEREAS, University desires to have the Patent Rights developed and
commercialized to benefit the public and is willing to grant a license hereunder. 
 NOW, THEREFORE, in consideration of the premises and the
mutual covenants contained herein, the parties hereto agree as follows: 
 ARTICLE 1. DEFINITIONS 
 For the purposes of this Agreement, the following words and phrases shall have the following meanings: 
  

	1.01	“Bucindolol” means the beta-adrenergic–receptor antagonist having the chemical formula:
2-{2-hydroxy-
3{{2-(3-indolyl)-1,1-dimethylethyl}amino}propoxy}-benzonitrile hydrochloride, and its racemates, isomers, prodrugs, active metabolites, analogs and any pharmaceutically acceptable salt or complex thereof, and diagnostics used in
connection with its prescription. 

  

 1 of 22 

	1.02	“Bucindolol Invention” shall mean an Invention relating solely to the use of Bucindolol as a therapeutic or as a diagnostic used solely in connection with the development
of Bucindolol. 

  

	1.03	“Effective Date” shall mean the date of the last signature on this Agreement. 

  

	1.04	“Fields of Use” shall mean the fields of use identified in Appendix B. 

  

	1.05	“Improvement” shall mean any invention in the field of human heart disease diagnosis, prevention and therapy, the practice of which would also require the practice of an
invention claimed in or covered by the Patent Rights, and which is a modification of the inventions claimed in or covered by the Patent Rights and is created in whole or in part by Michael Bristow. 

  

	1.06	“Invention” shall mean an invention in the field of human cardiovascular disease diagnosis, prevention and therapy conceived of or reduced to practice by University
employees Dr. Michael Bristow, so long as he is voluntarily involved in Licensee as an employee, consultant or director, or by Dr. Leslie Leinwand, and their University of Colorado collaborators (defined as those
 co-inventors indicated
on invention disclosure forms or individuals named in research grants obtained by Drs. Bristow and Leinwand). 

  

	1.07	“IVEP Invention” shall mean an Invention of a biological entity identified as being potentially involved in one or more disease states including, without limitation, any
human genes or gene products (including variants, post-translational modifications, isoforms and polymorphisms thereof) by Licensee by use of in vivo expression profiling techniques claimed by the Patent Rights. 

  

	1.08	“Know-How” shall mean, and be limited to, University’s proprietary information which has been created, developed, or fixed in any tangible medium of expression and
which is directly related to the use of, or desirable for the practice of, the Patent Rights. All Know-How due under this Agreement shall be delivered to Licensee prior to or on the Effective Date in written, electronic, oral or other form of
communication. 

  

	1.09	“Licensed Process(es)” shall mean any process, art, or method, that is covered in whole or in part by an issued, unexpired, valid and enforceable claim or a pending claim
contained in the Patent Rights or that incorporates or makes use of Know-How. 

  

	1.10	“Licensed Product(s)” shall mean any: 

  

	 	(a)	product or part thereof that is covered in whole or in part by an issued, unexpired, valid and enforceable claim or a pending claim contained in the Patent Rights or that
incorporates or makes use of Know-How; or 

  

	 	(b)	product, chemical composition, apparatus, or part thereof that is manufactured or discovered by using a Licensed
 Process(es) or is employed to practice a Licensed Process(es);
or 

  

 2 of 22 

	 	(c)	product produced, discovered, manufactured or created through the use of any Licensed Product defined in §1.010(a) or §1.010(b). 

  

	1.11	“Net Sales” shall mean the [ * ], whether invoiced or not, less [ * ]. Net sales shall also include the [ * ] received by Licensee as
determined by the [ * ]. 

  

	1.12	“Patent Rights” shall mean all of the following University intellectual property: 

  

	 	(a)	the United States and foreign patents and/or patent applications and/or provisional patent applications listed in
 Appendix A; and 

  

	 	(b)	United States and foreign patents issued from the applications listed in Appendix A and from divisionals and continuations of these applications; and

  

	 	(c)	claims of United States and foreign continuation-in-part applications, and of the resulting patents, which are directed to subject matter specifically described in the United States
and foreign applications listed in Appendix A; and 

  

	 	(d)	any reissues or reexaminations of United States and foreign patents described in (a), (b) or (c) above. 

  

	1.13	“Royalty” shall mean any consideration paid by Licensee pursuant to this Agreement. 

  

	1.14	“Territory” shall mean the geographical area identified in Appendix B. 

 ARTICLE 2. GRANT OF RIGHTS AND ACCEPTANCE 
  

	2.01	University hereby grants and Licensee accepts, during the term and subject to the terms and conditions of this Agreement, and further subject to University’s right to do so
without incurring liability to third parties: 

  

	 	(a)	an exclusive license to make, have made, use, sell, offer to sell and import the Know-How in the Territory and within the Fields of Use; and 

  

	 	(b)	an exclusive license of University’s Patent Rights, except for Patent Rights in University Case No. 2002.026H, in the Territory to make, have made, use, sell, offer to
sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use; and 

  

	 	(c)	an exclusive license of University’s Patent Rights in University Case No. 2002.026H in the Territory to make, have made, use, sell, offer to sell and import any Licensed
Products in the Fields of Use and to practice any Licensed Process in the Fields of Use (provided that such license may be converted into a co-exclusive license subject to Myogen’s right to obtain a co-exclusive license for such Patent Rights
from University). 

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 3 of 22 

	2.02	This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of University other than Patent Rights regardless of
whether such patents are dominant or subordinate to Patent Rights. 

  

	2.03	Improvements and New Inventions 

  

	 	(a)	Improvements. Subject to any preexisting contractual obligations, requirements of applicable law, and notwithstanding certain obligations to Myogen, Inc. (“Myogen”)
under Section 5.2 of the Intellectual Property Agreement, as amended, between University License Equity Holdings, Inc. (“ULEHI”) and Myogen, University reference #IR360H-03, dated November 23, 2003 (the
“Myogen-ULEHI Agreement”), Licensee shall have the option to include Improvements in the Patent Rights. Within thirty (30) days of notification by inventor(s) to University of an Improvement, University shall disclose such
Improvement to Licensee. Licensee shall have six (6) months from such disclosure to exercise the option, and shall reimburse University for all patent costs incurred prior to and during the option period. Upon exercise of the option, the
Improvement shall be deemed included in the Patent Rights licensed under this Agreement. If at the time of the invention of the Improvement a University researcher who is not a founder, employee or consultant of Licensee is named as an inventor on
any such Improvement, Licensee shall pay an acquisition payment of ten thousand dollars ($10,000) to University; however, such acquisition payment shall not exceed ten thousand dollars ($10,000) in total per Improvement, and said Improvement shall
be included in Patent Rights. Such acquisition payments shall be separate from Licensee’s obligations to pay patent costs and fees as described in Section 8 herein. 

  

	 	(b)	New Inventions. Subject to any preexisting contractual obligations or any amendments to the any of the Myogen agreements (if such amendment is agreed to by ARCA) and requirements of
applicable law, University hereby grants Licensee: 

  

	 	(1)	[ * ] option to license on commercially reasonable terms an IVEP Invention or a Bucindolol Invention; and 

  

	 	(2)	[ * ] option to license on commercially reasonable terms any Invention declined to be licensed by Myogen under the Myogen-ULEHI Agreement, as provided therein. The fee for
such options shall be [ * ] to University if a University researcher, who is also not a founder, employee or consultant of Licensee, is named as an inventor on any patent for each such Invention licensed by Licensee [ * ] and
such Invention shall be included in the Patent Rights. Such acquisition payments shall be separate from Licensee’s obligations to pay patent costs and fees as described in Section 8 herein. 

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 4 of 22 

	2.04	This Agreement shall be subject to the mandatory public laws in any country where this Agreement will produce an effect. 

 ARTICLE 3. SUBLICENSING 
  

	3.01	Upon notification by Licensee to University, Licensee may sublicense to one or more third parties the rights granted in Article 2 subject to the following limitations:

  

	 	(a)	Licensee agrees that any sublicenses granted by it shall impose restrictions and conditions upon sublicensees that are consistent with those imposed upon Licensee; and

  

	 	(b)	University agrees that, in the event University terminates this Agreement for any reason, any sublicenses granted shall survive such termination and shall be enforceable by both
University and sublicensee; and 

  

	 	(c)	Licensee agrees that any sublicenses granted shall adequately protect University’s security and property interest in University’s Know-How and Patent Rights.

  

	3.02	Any sublicenses granted by Licensee shall provide only for cash consideration from sublicensees unless University has expressly consented otherwise in writing in advance.

  

	3.03	Licensee agrees to forward to University a complete copy of each fully executed sublicense agreement postmarked within thirty (30) days of the execution of such agreement.

 ARTICLE 4. GOVERNMENT AND UNIVERSITY RIGHTS 
  

	4.01	Notwithstanding any use of descriptive terms within this Agreement such as “exclusive”, this Agreement is subject to all of the terms and conditions of Title 35 USC
§§ 200 et al (“Bayh-Dole Act”) and 37 CFR Part 401, as such may be amended. Further, Licensee agrees to take all reasonable action necessary to enable University to satisfy its obligations hereunder. Such terms and
conditions shall include Licensee’s obligation to assure that any Licensed Products used or sold in the United States shall be manufactured substantially in the United States. 

  

	4.02	University shall have the transferable right to practice the Patent Rights and Know-How for nonprofit research and education purposes. 

  

	4.03	University shall have the right to publish any information included in the Patent Rights and the Know-How provided that University takes reasonable steps to avoid the loss of any
patent rights as a result of University exercising its rights under this §4.03. 

  

 5 of 22 

 ARTICLE 5. ROYALTIES 
  

	5.01	As consideration for the disclosure of University’s Know-How as well as the licenses and rights under University’s Patent Rights, Licensee agrees to pay to University:

  

	 	(a)	nonrefundable Annual Minimum Royalties as set forth in Appendix C; and 

  

	 	(b)	Earned Royalties as set forth in Appendix C; and 

  

	 	(c)	Benchmark Royalties as set forth in Appendix C; and 

  

	 	(d)	Sublicensing Royalties as set forth in Appendix C. 

  

	5.02	No multiple Royalties shall be payable in the event that any Licensed Products or Licensed Processes are covered by more than one of the Patent Rights. 

  

	5.03	On sales of Licensed Products by Licensee to sublicensees or on sales made in other than arm’s-length transactions, the value of the Net Sales attributed under this Article 5
to such a transaction shall be that which would have been received in an arm’s-length transaction, based on a like transaction at that time. 

  

	5.04	Unless otherwise provided herein, all payments required under this Agreement shall be due within thirty (30) days of written notice from University. Payments past due shall
bear interest at the rate of one and one-half percent (1 1/2%) per month compounded, or the maximum interest rate allowed by applicable law, whichever is less. 

 ARTICLE 6. REPORTS, RECORDS AND AUDITS 
  

	 6.01
	 On or before the thirtieth (30th) day following the end of each calendar quarter during the term of this Agreement, Licensee shall provide to University written accounts of the Net Sales of Licensed Products and/or Licensed Processes subject to
Royalty hereunder made during the prior three (3) month period and shall simultaneously pay to University the Royalties due on such Net Sales, if any, in United States Dollars. Annual Minimum Royalties, if any, which are due University and
prorated for each calendar quarter, shall be paid by Licensee along with the written report due under this Agreement. The written report shall discuss the progress and results, as well as ongoing plans, with respect to the Licensed Products and/or
Licensed Processes. University shall have the right to request one meeting per year to discuss such information. Net Sales shall be reported in the format of Appendix D. 

  

	6.02	Licensee shall keep accurate records in sufficient detail to reflect its operations under this Agreement and to enable the Royalties accrued and payable under this Agreement to be
determined. Such records shall be retained for at least three (3) years after the close of the period to which they pertain, or for such longer time as may be required to finally resolve any question or discrepancy raised by University.

  

 6 of 22 

	6.03	Upon the request of University, with reasonable notice, but not more frequently than once a year, Licensee shall permit an independent public accountant selected and paid by
University to have access during regular business hours to such records as may be necessary to verify the accuracy of Royalty payments made or payable hereunder. Said accountant shall disclose information acquired to University only to the extent
that it should properly have been contained in the royalty reports required under this Agreement. If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then Licensee shall
reimburse University for the cost of the inspection and pay the amount of the underpayment including any interest as required by this Agreement. If an inspection shows an overpayment of Royalties, such sums shall be applied to and deducted from the
following Royalty payments, or subsequent payments, until the overpayment has been extinguished. 

  

	6.04	Licensee acknowledges that University is subject to the Colorado Public Records Act (C.R.S. §§ 24-72-201 et seq.). All plans and reports marked “Confidential”
shall be treated by University as confidential to the extent permitted under §§ 24-72-204. 

  

	6.05	Each party shall vigilantly protect the confidential information related to the Patent Rights and Know-How from disclosure to third parties; and no such disclosure shall be made
except under sufficiently protective confidentiality agreements. All written documents containing confidential information and other material in tangible form, as well as oral communications containing confidential information received by either
party under this Agreement shall be disclosed only pursuant to such confidentiality agreements and shall remain the property of the disclosing party, and such documents and materials, together with copies of excerpts thereof, shall promptly be
returned to disclosing party upon request, except one copy may be retained for archival purposes. This section shall cover oral communications containing confidential information provided that such oral communications containing confidential
information are summarized in writing by the disclosing party and provided to the recipient within thirty (30) days of such oral disclosure. 

 ARTICLE 7. DUE DILIGENCE AND PERFORMANCE 
  

	7.01	Licensee shall use commercially reasonable efforts to proceed with the development, manufacture, exploitation and sale or lease of Licensed Products and Licensed Processes and to
diligently develop markets for the Licensed Products and Licensed Processes throughout the term of this Agreement. Licensee acknowledges and agrees to the performance milestones defined in Appendix E. 

  

	7.02	Licensee agrees to develop a vigorous sublicensing program to effect commercialization of Licensed Products and Licensed Processes in any Field of Use or Territory that Licensee
decides not to exploit for itself, subject to commercial constraints and Licensee’s reasonable business judgment. 

  

	7.03	University may terminate this Agreement or convert this Agreement to a non-exclusive Agreement if Licensee fails to meet any of the due diligence or performance requirements of this
Article 7, subject to provisions of section 10.03(c). 

  

 7 of 22 

 ARTICLE 8. PATENTS, COSTS, AND ENFORCEMENT 
  

	8.01	Licensee shall [ * ] University, within thirty (30) days of University’s invoice, an [ * ]. 

  

	8.02	Licensee shall control and diligently pursue the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Patent Rights on or
after the Effective Date, using patent counsel of its choice. Licensee shall [ * ], except as otherwise provided in this Article 8. 

  

	8.03 (a)	Licensee shall keep University advised as to the status of the Patent Rights by providing University, in a timely manner prior to their due date, with copies of all official
documents and material correspondence relating to the prosecution, maintenance, and validity of any patent applications and patents included in the Patent Rights. University shall have reasonable opportunities to consult with Licensee on such patent
applications and patents and shall provide such other reasonable assistance from time to time at the request of Licensee as necessary to file, prosecute and maintain such applications, at Licensee’s expense. Licensee shall diligently seek
legally appropriate claims under the Patent Rights, and shall not abandon prosecution of any patent application without first notifying University a reasonable time in writing prior to any bar date, of Licensee’s intention and reason therefor,
and providing University with reasonable opportunity to assume responsibility for prosecution, maintenance and associated costs of such patents and patent applications. If University pursues such patent protection, then from that time forward all
such subject patent applications and any patents arising therefrom shall be excluded from the Patent Rights under this Agreement and Licensee shall forfeit all rights under this Agreement to such patent applications and any patents arising
therefrom. 

  

	 	(b)	No claims of the filed patent applications or issued patent or foreign patent rights constituting Patent Rights hereunder shall be modified, deleted, or abandoned by Licensee or its
patent counsel without reasonable, prior written notice to University and reasonable opportunity for University to consult with Licensee. Licensee’s obligations under this §8.03 shall include, without limitation, an obligation to inform
University in a timely manner if Licensee will not pursue patents in any foreign countries where patent protection may be available, in order that University may prosecute patents in such countries if University so desires. If University pursues
such foreign patent protection, or an issued patent which Licensee intends to abandon, then from that time forward such subject patent applications and any patents arising therefrom, or such issued patents, shall no longer be considered Patent
Rights under this Agreement and Licensee shall forfeit all rights under this Agreement to such patent applications, any patents arising therefrom, or such issued patents. University shall be [ * ] with those patent applications and patents
it decides to pursue and maintain. 

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 8 of 22 

	8.04	If Licensee fails to diligently prosecute the Patent Rights, University may provide Licensee with written notice that University wishes to resume control of the preparation, filing,
prosecution, and maintenance of any and all patent applications or patents included in the Patent Rights. If University elects to resume such responsibilities, Licensee agrees to cooperate fully with University, its attorneys, and agents in
preparation, filing, prosecution, and maintenance of any and all patent applications or patents and to provide University with complete copies of any and all documents or other materials that University deems necessary to undertake such
responsibilities. 

  

	8.05	University and Licensee agree to inform the other party promptly in writing of any suspected infringement of the Patent Rights by a third party. Licensee shall have, for a period of
[ * ] from the date of any notice of infringement of the Patent Rights, the first right to institute suit against such third party. If Licensee institutes such a suit, it shall bear all costs of the litigation and shall be entitled to
retain the entire amount of any recovery or settlement less earned royalties due to University. Thereafter, University and Licensee shall each have the right to institute an action for infringement of the Patent Rights against such third party in
accordance with the following: 

  

	 	(a)	If both University and Licensee agree to institute suit jointly, the suit shall be brought in both their names, the out-of-pocket costs thereof shall be borne equally, and any
recovery or settlement shall be shared equally. University and Licensee shall agree to the manner in which they shall exercise control over such suit. Each party, at its option, may be represented by separate counsel of its own selection, the fees
for which shall be paid for by the respective parties; 

  

	 	(b)	In the absence of an agreement to institute a suit jointly, University may, but is not obligated to, institute suit, and at its option, join Licensee as a plaintiff. If University
decides to institute suit, it shall notify Licensee in writing. Licensee’s failure to notify University in writing within fifteen (15) days after the date of University’s notice, that it will join in enforcing the Patent Rights
pursuant to the terms hereof, shall be deemed conclusively to be Licensee’s assignment to University of all rights, causes of action, and damages resulting from any such alleged infringement. University shall bear the entire cost of such
litigation and shall be entitled to retain the entire amount of any recovery or settlement; 

  

	 	(c)	In the absence of an agreement to institute a suit jointly, and if University does not notify Licensee of its intent to pursue legal action within ninety (90) days of the end
of the one hundred twenty (120) day period as provided above, Licensee may institute suit. Licensee shall bear the entire cost of such litigation and shall be entitled to retain the entire amount of any recovery or settlement less earned
royalties due University; 

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 9 of 22 

	 	(d)	If Licensee undertakes to defend the Patent Rights by litigation, Licensee may defer from its royalty payments to University with respect to the Patent Rights subject to suit an
amount not exceeding fifty percent (50%) of Licensee’s expenses and costs of such action, including reasonable attorney’s fees, provided however, that such deferral shall not exceed fifty percent (50%) of the total royalty due to
University for each calendar year, and that such deferred payments shall be delivered to University upon settlement of the litigation. 

  

	8.06	In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Patent Rights shall be brought against Licensee or raised by way of
counterclaim or affirmative defense in an infringement suit brought by Licensee under § 8.05, pursuant to this Agreement and the provisions of Chapter 29 of Title 35, U.S. Code or other statutes, or in the case of any action against Licensee
alleging infringement by the Licensed Products or Licensed Processes, Licensee may: 

  

	 	(a)	defend the suit in its own name, at its own expense, and on its own behalf and collect for its use, damages, profits, and awards of whatever nature recoverable for such claims
consistent with §8.05; and 

  

	 	(b)	settle any claim or suit for declaratory judgment involving the Patent Rights, except that Licensee shall have no right to deny the validity of any patent, patent claim, or patent
application included in the Patent Rights in any compromise or settlement of any claim or suit for declaratory judgment without the express prior written consent of University; provided however, that 

 University shall have a continuing right to intervene in such actions described in subparagraphs (a) and (b). Licensee shall take no action to compel
University either to initiate or to join in any such declaratory judgment action. If Licensee elects not to defend against such declaratory judgment action, University, at its option, may do so at its own expense and shall be entitled to retain the
entire amount of any recovery or settlement. 
  

	8.07	In all cases, Licensee agrees to keep University reasonably apprised of the status and progress of any litigation. 

 ARTICLE 9. NO WARRANTIES, INDEMNIFICATIONS AND INSURANCE 
  

	9.01	UNIVERSITY MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER
DISPOSITION BY LICENSEE, SUBLICENSEE(S), OR THEIR VENDEES OR OTHER TRANSFEREES OF LICENSED PRODUCTS OR LICENSED PROCESSES INCORPORATING OR MADE BY USE OF THE PATENT RIGHTS. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE, OR THAT THE USE OR SALE OF SUCH PRODUCTS OR PROCESSES WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, SERVICE MARK, OR OTHER RIGHTS. 

  

 10 of 22 

	9.02	Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement shall be construed as: 

  

	 	(a)	A warranty or representation by University as to rights in Know-How or the validity or scope of any of the Patent Rights; 

  

	 	(b)	A warranty or representation that the Patent Rights or anything made, used, sold or otherwise disposed of under the License will or will not infringe patents, copyrights or other
rights of third parties; or 

  

	 	(c)	An obligation to furnish any know-how or technology not agreed to in this Agreement, to bring or prosecute actions or suits against third parties for infringement (except to the
extent described in §8.05) or to provide any services other than those specified in this Agreement. 

  

	9.03	Licensee shall indemnify, defend, and hold harmless University, its regents, employees, students, officers, agents, affiliates, and representatives from and against all liability,
demands, damages, losses, and expenses, for death, personal injury, illness, property damage, noncompliance with applicable laws and any other claim, proceeding, demand, expense and liability of any kind whatsoever in connection with or arising out
of: 

  

	 	(a)	the use by or on behalf of Licensee, its sublicensees, affiliates, directors, officers, employees, or third parties of any Patent Rights; or 

  

	 	(b)	the design, manufacture, production, distribution, advertisement, consumption, sale, lease, sublicense or use of any Licensed Product(s), Licensed Process(es) or materials by
Licensee, or other products or processes developed in connection with or arising out of the Patent Rights; or 

  

	 	(c)	any right or obligation of Licensee under this Agreement. 

  

	9.04	Licensee shall obtain general liability insurance, including product liability insurance, on such terms and in such amounts as are reasonable and customary within the industry.

 ARTICLE 10. DURATION AND TERMINATION 
  

	10.01 	The term of the License shall commence on the Effective Date and extend to the date of expiration of the last to expire of any patents embodying the Licensed Products or Licensed
Processes, including any continuations, continuations-in-part, reissues, renewals or extensions thereof. The obligation to pay the Royalty set forth under Article 5 with respect to each Licensed Product or Licensed Process shall expire when the
patent covering such Licensed Product or Licensed Process expires. 

  

 11 of 22 

	10.02 	Licensee may terminate this Agreement at any time on sixty (60) days written notice to University if Licensee: 

  

	 	(a)	pays all amounts due, including the pro-rata Annual Minimum Royalties, as well as all non-cancelable costs, to University through the termination date; 

  

	 	(b)	submits a final report of the type described in Article 6; 

  

	 	(c)	returns any confidential materials provided to Licensee by University in connection with this Agreement; 

  

	 	(d)	suspends its use and sales of the Licensed Product(s) and Licensed Process(es); provided, however, that Licensee may for a period of one hundred and eighty (180) days after the
effective date of such termination sell all Licensed Products that may be in inventory subject to Licensee’s obligations in Article 5 and Article 6; and 

  

	 	(e)	provides University the right to access any regulatory information filed with any U.S. or foreign government agency with respect to Licensed Products and Licensed Processes.

  

	10.03 	University may terminate this Agreement in the event that: 

  

	 	(a)	Licensee fails to pay University any amounts when due to University hereunder and Licensee fails to make such payment within sixty (60) days of written notice from University;
or 

  

	 	(b)	Licensee becomes insolvent, files a Chapter 7 petition in bankruptcy, has such a petition filed against it, and such petition is not dismissed within ninety (90) days; or

  

	 	(c)	Licensee is in material breach or default of this Agreement other than those occurrences listed in §10.03 (a) or (b), and Licensee fails to cure the breach or default
within sixty (60) days of written notice of the breach or default. Licensee’s ability to cure such breach shall be limited to the first two material breaches properly noticed under the terms of this Agreement, regardless of the nature of
those breaches. Any subsequent material breach shall entitle University to terminate this Agreement immediately. Events constituting a material breach or default shall include, but are not limited to, the following: 

  

	 	(i)	failure by Licensee to meet any performance milestone in Appendix E; 

  

	 	(ii)	operation, manufacture, use of or sale of the Licensed Products or Licensed Processes outside the Fields of Use or Territory; 

  

	 	(iii)	failure to keep adequate records or permit inspection or audit. 

  

 12 of 22 

 ARTICLE 11. MISCELLANEOUS 
  

	11.01 	This Agreement shall be governed by and construed in accordance with the laws of the State of Colorado. 

  

	11.02 	All notices, demands or consents required or permitted hereunder shall be deemed sufficient if given in writing and personally delivered, sent by registered mail, postage prepaid,
or by a nationally recognized overnight courier service, and addressed to the party to receive such notice at the address given below, or such other address as may hereafter be designated by notice in writing. 

  

			
	University:	  	Licensee:
		
	 Technology Transfer Office
 University of Colorado, 588
SYS 
 Suite 390, 4001 Discovery Drive
 Boulder, CO 80309-0588

 <License Administrator, Case #s 2002.026H, CU1297H, CU1298H>
  
 Electronic funds transfer can be made to:
  
 Routing Transit Number (RTN): [ * ]
 Account Number: [ * ]

 Bank Name: [ * ]
 City, State:
[ * ]
 Payee/beneficiary: [ * ]
 Attention:
[ * ]
  
 Please include sufficient information to identify payment. Licensee is
responsible for electronic transfer expenses.
	  	 ARCA Discovery, Inc.
 1400 16th Street, Suite 220
 Denver, CO 80202
 Attention: Dr. Michael Bristow

  

	11.03 	Licensee agrees not to identify University in any promotional advertising, press releases, sales literature or other promotional materials to be disseminated to the public or any
portion thereof without University’s prior written consent in each case, except that Licensee may state that it has a license for the Patent Rights from University. Licensee further agrees not to use the name of University or any University
faculty member, inventor, employee or student or any trademark, service mark, trade name, copyright or symbol of University, without the prior written consent of the University, entity or person whose name is sought to be used.

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 13 of 22 

	11.04 	Licensee agrees to: 

  

	 	(a)	cause Licensed Products or the product of Licensed Processes sold under this Agreement to be marked with the notice of the patent numbers or patent pending, as may be appropriate;

  

	 	(b)	comply with all laws and regulations of the United States and any other country as appropriate concerning or controlling the import or export of the Licensed Products, data,
software, laboratory prototypes or other commodities. University makes no representation that a license or consent for export will not be required by applicable governmental agencies, or if required, that it will be issued; and

  

	 	(c)	comply with all applicable statutes, regulations, and guidelines, including applicable governmental regulations, policies and guidelines in its use of any University - supplied
materials (“Materials”). Licensee agrees not to use the Materials for research involving human subjects or clinical trials in the United States without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46 (as those regulations may be
amended from time to time). Licensee agrees not to use the Materials for research involving human subjects or clinical trials outside of the United States without notifying University in writing, of such research or trials and complying with the
applicable regulations of the appropriate national control authorities. Written notification to University of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior
to commencement of such research or trials. 

  

	11.05 	In the event of any dispute arising out of or relating to this Agreement, the affected party shall promptly notify the other party in writing, and upon the other party’s
receipt of such notice (“Notice Date”), the parties shall attempt in good faith to resolve the matter. Any disputes not so resolved shall be referred to senior executives of the parties, who shall meet at a mutually acceptable time
and location within thirty (30) days of the Notice Date and shall attempt to mediate the dispute and negotiate a settlement. If the senior executives fail to meet within thirty (30) days of the Notice Date, or if the matter remains
unresolved for a period of sixty (60) days after the Notice Date, the dispute may be submitted to a court of competent jurisdiction in the State of Colorado, and, by execution and delivery of this Agreement, each party (a) accepts,
generally and unconditionally, the jurisdiction of such court and any related appellate court, and (b) irrevocably waives any objection it may now or hereafter have as to the venue of any such suit, action or proceeding brought in such court or
that such court is an inconvenient forum. However, either party shall be free to seek appropriate injunctive relief without compliance with the mediation procedures set forth herein. 

  

	11.06 	The terms and provisions contained in this Agreement constitute the entire Agreement between the parties and shall supersede all previous communications, representations, agreements
or understandings, either oral or written, between the parties hereto with respect to the subject matter hereof, and no agreement or understanding varying or extending this Agreement will be binding upon either party hereto, unless in writing which
specifically refers to this Agreement, signed by duly authorized officers or representatives of the respective parties, and the provisions of this Agreement not specifically amended thereby shall remain in full force and effect according to their
terms. 

  

 14 of 22 

	11.07 	The provisions and clauses of this Agreement are severable, and in the event that any provision or clause is determined to be invalid or unenforceable under any controlling body of
the law, such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining provisions and clauses hereof. 

  

	11.08 	This Agreement does not establish a joint venture, agency or partnership between the parties, nor create an employer - employee relationship. This Agreement may be assigned to a
party that acquires substantially all of the assets of Licensee upon thirty (30) days prior written notice to University. A change in control of Licensee shall not be considered an assignment of this Agreement. 

  

	11.09 	The parties agree that nothing in this Agreement is intended or shall be construed as a waiver, either express or implied, of any of the immunities, rights, benefits, defenses or
protections provided to University under governmental or sovereign immunity laws from time to time applicable to University, including, without limitation, the Colorado Governmental Immunity Act (C.R.S. §§24-10-101, et seq.) and the
Eleventh Amendment to the United States Constitution. 

  

	11.10 	The provisions of Articles 1, 8 and 11, and §§ 6.01, 6.02, 9.01-9.03, and any other provision of this Agreement that by its nature is intended to survive, shall survive
any termination or expiration of this Agreement. 

  

 15 of 22 

 IN WITNESS WHEREOF the parties hereto have caused this Agreement, which is effective on the date of the
last to sign below, to be executed in duplicate by their respective duly authorized officers. 
  

									
	University:	 		 	Licensee:
			
		 		 	ARCA Discovery, Inc.
					
	By:	 	/s/ David N Allen	 		 	By:	 	/s/ Timothy D. Hoogheem
	Title:	 	Associate VP	 		 	Title:	 	Chief Business & Financial Officer
	Date:	 	October 14, 2005	 		 	Date:	 	October 14, 2005

  

 16 of 22 

 APPENDIX A 
 PATENT RIGHTS 
  

					
	 CU ID #
	  	Patent #	  	Title, Inventors
	 2002.026H
	  	[ * ]	  	[ * ]
			
	 2002.026H
	  	[ * ]	  	[ * ]
			
	 2002.026H
	  	[ * ]	  	[ * ]
			
	 2002.026H
	  	[ * ]	  	[ * ]
			
	 2002.026H
	  	[ * ]	  	[ * ]
			
	 2002.026H
	  	[ * ]	  	[ * ]
			
	 CU1297H
	  	[ * ]	  	[ * ]
			
	 CU1298H
	  	[ * ]	  	[ * ]
			
	 CU1297H/
 CU1298H
	  	[ * ]	  	[ * ]

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 17 of 22 

 APPENDIX B 
 FIELDS OF USE and TERRITORY 
 Territory = worldwide 
 Fields of Use = all fields 
  

 18 of 22 

 APPENDIX C 
 ROYALTIES 
 In accordance with Articles 5 and 6, Licensee shall pay the following Royalties to University:

 Annual Minimum Royalty: [ * ] until first commercial sales of Licensed Product(s) and/or Licensed Process(es) occurs, payable quarterly in
accordance with section 6.01; [ * ] of Licensed Product(s) and/or Licensed Process(es), payable quarterly in accordance with section 6.01. The Annual Minimum Royalty will be credited against any Earned Royalties that are payable for each
reporting period. 
 Earned Royalty: A percentage of Net Sales as follows: [ * ] of Net Sales. If the Licensed Product or Licensed Process is sold
as a combination product, or as a part of bundled products, in such a way that the price of the Licensed Product or Licensed Process included in the combination product is not separately stated on the invoice, for the purpose of determining
[ * ] payments, Net Sales for the combination product, or bundled products, shall be determined by multiplying Net Sales of the combination product by the fraction [ * ]. If such [ * ] are not established, then the
parties shall negotiate in good faith to determine the method of calculating Net Sales for combination products. No [ * ] shall be payable on Bucindolol. 
 Benchmark Royalties: Payable within thirty (30) days of each event, as follows: 
 (a) With respect to the
[ * ] involving any Licensed Product(s) and/or Licensed Process(es) (excluding Bucindolol), [ * ]. 
 (b) With respect to
the [ * ] involving any Licensed Product(s) and/or Licensed Process(es) (excluding Bucindolol), [ * ]. 
 (c) With
respect to the [ * ] any Licensed Product(s) and/or Licensed Process(es) [ * ] (excluding Bucindolol), [ * ]. 
 Sublicensing Royalties: Licensee shall pay University Sublicensing Royalties for all sublicense consideration received for the sublicense of the Patent Rights (excluding Bucindolol, and other than the sublicense of the Patent Rights
to any Affiliates of Licensee) according to the following schedule: (a) [ * ], (b) [ * ] and (c) [ * ]. For purposes of this Agreement, an “Affiliate” shall mean every corporation, or entity,
which, directly or indirectly, or through one or more intermediaries, controls, is controlled by, or is under common control with Licensee, as well as every officer, director, agent and representative of any such corporation or entity. For the
purposes of the definition of Affiliate, the word “control” (including, with correlative meaning, the terms “controlled by” or “under common control with”) means the actual power, either directly or 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 19 of 22 

 indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such
entity, whether by ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 
 Notwithstanding the
foregoing, the exclusion of Royalties on Bucindolol shall apply to the Patent Rights but shall not apply to Improvements or other new Inventions involving Bucindolol that are created with the use of University facilities. 
  

 20 of 22 

 APPENDIX D 
 ROYALTY REPORT 
  

									
	Licensee:	 	 	 		 	Case No.:	  	 
	Inventor:	 	 	 		 	Patent No.	  	 
	Period Covered: From:	 	                        /             /	 		 	Through:	  	                        /            /
	Prepared By:	 	 	 		 	Date:	  	 
	Approved By:	 	 	 		 	Date:	  	 

 If license covers several major product lines, please prepare a separate report for each line. Then combine all
product lines into a summary report. A discussion of the progress and results, as well as ongoing plans, with respect to the Licensed Products and/or Licensed Processes, see § 6.01, is attached. 
  

			
	 Report Type:
	  	 ____ Single Product Line Report: _____________________________________________
 ____ Multiproduct Summary Report. Page 1 of _____ Pages
 ____ Product Line Detail. Line: ____________ Trademark: ___________
Pages: _____

  

													
	 	  	Gross
Sales	  	* Less:
Allowances	  	Net
Sales	  	Royalty
Rate	  	Period Royalty Amount
	 Country
	  	  	  	  	  	This Year	  	Last Year
	 U.S.A.
	  		  		  		  		  		  	
	 Canada
	  		  		  		  		  		  	
	 Europe
	  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
	 Japan
	  		  		  		  		  		  	
	 Other:
	  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
	 TOTAL:
	  		  		  		  		  		  	

 Sublicense Fees this quarter: $________ (attach page showing names, addresses, and telephone numbers; and amount
of fees received; territory; field of use) 
 Total Royalty: $________ 
 The following royalty forecast is non-binding and for University internal planning purposes only: 
 Royalty Forecast Under This Agreement:

 Next Quarter:_________ Q2:__________ Q3: ________ Q4: _________ 
  

 21 of 22 

 APPENDIX E 
 PERFORMANCE MILESTONES 
 Licensee agrees to the following: 
  

	 	a.	On or before [ * ], Licensee shall deliver to University a business plan that communicates the Licensee’s product development and marketing (strategic, tactical and
financial) plans for Patent Rights. This document shall include forecasts showing the funds, personnel and time budgeted and planned for development of the Licensed Product(s) and Licensed Process(es) and Licensee shall provide similar reports or
updates, as the case may be, to University on [ * ]. 

  

	 	b.	Licensee agrees that if any particular patent application or issued patent that is a part of the Patent Rights is not developed, sublicensed or being diligently used in research and
development within [ * ] of the filing of the respective patent application, Licensee shall relinquish all rights to that portion of the Patent Rights to University without additional compensation, credit or refund of any amounts paid.

  

	 	c.	Within [ * ] of the Effective Date, Licensee shall have raised a total of at least [ * ]. 

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 22 of 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]